Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis

Cardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late‐stage cardiac AL amyloidosis. The primary end points were over...

Descripción completa

Detalles Bibliográficos
Autores principales: Brennan, Xavier, Withers, Barbara, Jabbour, Andrew, Milliken, Sam, Kotlyar, Eugene, Fay, Keith, Ma, David, Muthiah, Kavitha, Hamad, Nada, Dodds, Anthony, Bart, Nikki, Keogh, Anne, Hayward, Chris, Macdonald, Peter, Moore, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828809/
https://www.ncbi.nlm.nih.gov/pubmed/36266066
http://dx.doi.org/10.1111/imj.15926
Descripción
Sumario:Cardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late‐stage cardiac AL amyloidosis. The primary end points were overall survival and haematological response. Both regimens provided meaningful responses in this difficult to treat patient group.

Ejemplares similares